| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Rationale : Bone marrow-derived endothelial progenitor cells (EPCs) play an important role in angiogenesis and tumor growth. However, the clinical relevance of EPCs in blood vessel formation in non-small cell lung cancer (NSCLC) remains unclear. We assessed the hypothesis that EPC numbers are increased in NSCLC patients and correlate with clinicopathological factors.
Methods : EPCs labeled with CD34, CD133, and vascular endothelial growth factor receptor-2 antibodies were counted by flow cytometiry in the peripheral blood of 30 NSCLC patients. We examined age, pathological stage, histological type, Fluoro-D-glucose Positron emission tomography (FDG-PET), response to therapy, and tumor size of NSCLC patients, and investigated whether these factors correlate with EPC counts.
Results : Circulating EPC numbers before antitumor therapy were increased in NSCLC patients compared with healthy controls (p<0.05). Furthermore, in the subgroup of responders to treatment, EPC numbers were significantly lower than in non-responder patients receiving antitumor therapy (p<0.05). However, no significant associations with age, gender, histological type, pathological stage, or FDG-PET were detected.
Conclusions : Peripheral blood levels of bone marrow-derived EPCs are significantly increased in patients with NSCLC, and correlate with response to antitumor therapy.
|
